By: IPP Bureau
Last updated : August 26, 2025 9:43 am
Bristol Myers Squibb announced that new clinical and real-world data from its cardiovascular portfolio will be presented at the European Society of Cardiology (ESC) Congress 2025, being held from August 29 to September 1 in Madrid, Spain.
The presentations will include important updates on Camzyos for hypertrophic cardiomyopathy (HCM) and Eliquis (apixaban), which is being developed with Pfizer.
“With a 70-year legacy in cardiovascular medicine, we are deeply committed to advancing life-changing therapies for patients, including those living with symptomatic obstructive HCM,” said Roland Chen, senior vice president, Drug Development, Immunology and Cardiovascular, Bristol Myers Squibb. “Camzyos is the first and only cardiac myosin inhibitor supported by long-term extension and real-world data. The evidence continues to show improvements in symptoms, functional capacity, and cardiac structure across diverse patient populations. We look forward to sharing new data at ESC that reinforce its safety and benefit profile globally.”
The data being presented will cover real-world outcomes from the COLLIGO-HCM study conducted across five countries, pooled analysis of Camzyos monotherapy from four Phase 3 studies, and late-breaking results from the ODYSSEY-HCM trial, the largest and longest Phase 3 study in non-obstructive HCM with 580 patients. Additional findings will also be shared on cardiac imaging, biomarkers, and registry data.
For Eliquis, new findings include results from the DEFINE-AF study on home-based atrial fibrillation screening in elderly hypertensive patients, as well as analyses on risks and outcomes associated with new-onset atrial fibrillation following myocardial infarction.
Camzyos is currently approved in the United States, European Union, and more than 50 other countries for adults with NYHA class II–III obstructive HCM, and continues to be studied in broader patient populations. Eliquis remains a leading oral anticoagulant worldwide, approved for stroke prevention in atrial fibrillation and the treatment and prevention of venous thromboembolism.
Camzyos is the first and only cardiac myosin inhibitor, designed to address the underlying cause of HCM by reducing excessive myosin-actin cross-bridge formation. In obstructive HCM, it has been shown to reduce left ventricular outflow tract obstruction, improve cardiac filling pressures, and increase overall functional capacity.
Eliquis is an oral selective Factor Xa inhibitor that prevents clot formation. It is approved for several uses worldwide, including prevention of stroke in patients with non-valvular atrial fibrillation (NVAF), and for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).